Literature DB >> 25519688

Reduced dietary salt for the prevention of cardiovascular disease.

Alma J Adler1, Fiona Taylor, Nicole Martin, Sheldon Gottlieb, Rod S Taylor, Shah Ebrahim.   

Abstract

BACKGROUND: This is an update of a Cochrane review that was first published in 2011 of the effects of reducing dietary salt intake, through advice to reduce salt intake or low-sodium salt substitution, on mortality and cardiovascular events.
OBJECTIVES: 1. To assess the long-term effects of advice and salt substitution, aimed at reducing dietary salt, on mortality and cardiovascular morbidity.2. To investigate whether a reduction in blood pressure is an explanatory factor in the effect of such dietary interventions on mortality and cardiovascular outcomes. SEARCH
METHODS: We updated the searches of CENTRAL (2013, Issue 4), MEDLINE (OVID, 1946 to April week 3 2013), EMBASE (OVID, 1947 to 30 April 2013) and CINAHL (EBSCO, inception to 1 April 2013) and last ran these on 1 May 2013. We also checked the references of included studies and reviews. We applied no language restrictions. SELECTION CRITERIA: Trials fulfilled the following criteria: (1) randomised, with follow-up of at least six months, (2) the intervention was reduced dietary salt (through advice to reduce salt intake or low-sodium salt substitution), (3) participants were adults and (4) mortality or cardiovascular morbidity data were available. Two review authors independently assessed whether studies met these criteria. DATA COLLECTION AND ANALYSIS: A single author extracted data and assessed study validity, and a second author checked this. We contacted trial authors where possible to obtain missing information. We extracted events and calculated risk ratios (RRs) and 95% confidence intervals (CIs). MAIN
RESULTS: Eight studies met the inclusion criteria: three in normotensives (n = 3518) and five in hypertensives or mixed populations of normo- and hypertensives (n = 3766). End of trial follow-up ranged from six to 36 months and the longest observational follow-up (after trial end) was 12.7 years.The risk ratios (RR) for all-cause mortality in normotensives were imprecise and showed no evidence of reduction (end of trial RR 0.67, 95% confidence interval (CI) 0.40 to 1.12, 60 deaths; longest follow-up RR 0.90, 95% CI 0.58 to 1.40, 79 deaths n=3518) or in hypertensives (end of trial RR 1.00, 95% CI 0.86 to 1.15, 565 deaths; longest follow-up RR 0.99, 95% CI 0.87 to 1.14, 674 deaths n=3085). There was weak evidence of benefit for cardiovascular mortality (hypertensives: end of trial RR 0.67, 95% CI 0.45 to 1.01, 106 events n=2656) and for cardiovascular events (hypertensives: end of trial RR 0.76, 95% CI 0.57 to 1.01, 194 events, four studies, n = 3397; normotensives: at longest follow-up RR 0.71, 95% CI 0.42 to 1.20, 200 events; hypertensives: RR 0.77, 95% CI 0.57 to 1.02, 192 events; pooled analysis of six trials RR 0.77, 95% CI 0.63 to 0.95, n = 5912). These findings were driven by one trial among retirement home residents that reduced salt intake in the kitchens of the homes, thereby not requiring individual behaviour change.Advice to reduce salt showed small reductions in systolic blood pressure (mean difference (MD) -1.15 mmHg, 95% CI -2.32 to 0.02 n=2079) and diastolic blood pressure (MD -0.80 mmHg, 95% CI -1.37 to -0.23 n=2079) in normotensives and greater reductions in systolic blood pressure in hypertensives (MD -4.14 mmHg, 95% CI -5.84 to -2.43 n=675), but no difference in diastolic blood pressure (MD -3.74 mmHg, 95% CI -8.41 to 0.93 n=675).Overall many of the trials failed to report sufficient detail to assess their potential risk of bias. Health-related quality of life was assessed in one trial in normotensives, which reported significant improvements in well-being but no data were presented. AUTHORS'
CONCLUSIONS: Despite collating more event data than previous systematic reviews of randomised controlled trials, there is insufficient power to confirm clinically important effects of dietary advice and salt substitution on cardiovascular mortality in normotensive or hypertensive populations. Our estimates of the clinical benefits from advice to reduce dietary salt are imprecise, but are larger than would be predicted from the small blood pressure reductions achieved. Further well-powered studies would be needed to obtain more precise estimates. Our findings do not support individual dietary advice as a means of restricting salt intake. It is possible that alternative strategies that do not require individual behaviour change may be effective and merit further trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25519688      PMCID: PMC6483405          DOI: 10.1002/14651858.CD009217.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  85 in total

Review 1.  Sodium, potassium, calcium and magnesium and cardiovascular risk.

Authors:  F P Cappuccio
Journal:  J Cardiovasc Risk       Date:  2000-02

2.  Salt intake, hypertension and risk of cardiovascular disease: an important public health challenge.

Authors:  Jiang He; Paul K Whelton
Journal:  Int J Epidemiol       Date:  2002-04       Impact factor: 7.196

3.  Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program.

Authors:  Paul K Whelton; Jiang He; Lawrence J Appel; Jeffrey A Cutler; Stephen Havas; Theodore A Kotchen; Edward J Roccella; Ron Stout; Carlos Vallbona; Mary C Winston; Joanne Karimbakas
Journal:  JAMA       Date:  2002-10-16       Impact factor: 56.272

4.  Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE).

Authors:  L J Appel; M A Espeland; L Easter; A C Wilson; S Folmar; C R Lacy
Journal:  Arch Intern Med       Date:  2001-03-12

5.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.

Authors:  F M Sacks; L P Svetkey; W M Vollmer; L J Appel; G A Bray; D Harsha; E Obarzanek; P R Conlin; E R Miller; D G Simons-Morton; N Karanja; P H Lin
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

6.  Predictors and mediators of successful long-term withdrawal from antihypertensive medications. TONE Cooperative Research Group. Trial of Nonpharmacologic Interventions in the Elderly.

Authors:  M A Espeland; P K Whelton; J B Kostis; J L Bahnson; W H Ettinger; J A Cutler; L J Appel; S Kumanyika; D Farmer; J Elam; A C Wilson; W B Applegate
Journal:  Arch Fam Med       Date:  1999 May-Jun

7.  Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.

Authors:  Giuseppe Licata; Pietro Di Pasquale; Gaspare Parrinello; Antonietta Cardinale; Angela Scandurra; Giuseppe Follone; Christiano Argano; Antonino Tuttolomondo; Salvatore Paterna
Journal:  Am Heart J       Date:  2003-03       Impact factor: 4.749

Review 8.  Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride.

Authors:  G Jürgens; N A Graudal
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 9.  Advice to reduce dietary salt for prevention of cardiovascular disease.

Authors:  L Hooper; C Bartlett; Smith G Davey; S Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2004

10.  Feasibility of a long-term low-sodium diet in mild hypertension.

Authors:  C Alli; F Avanzini; G Bettelli; M Bonati; F Colombo; R Corso; M Di Tullio; M G Gentile; L Sangalli; E Taioli
Journal:  J Hum Hypertens       Date:  1992-08       Impact factor: 3.012

View more
  36 in total

Review 1.  Primary and secondary prevention of ischemic heart disease in women.

Authors:  Priya Kohli
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

2.  [Salt restriction in people with hypertension and patients with cardiovascular disease : meaningfulness and extent].

Authors:  J Hoyer
Journal:  Internist (Berl)       Date:  2015-07       Impact factor: 0.743

3.  Dietary Sodium and Cardiovascular Disease Risk--Measurement Matters.

Authors:  Mary E Cogswell; Kristy Mugavero; Barbara A Bowman; Thomas R Frieden
Journal:  N Engl J Med       Date:  2016-06-01       Impact factor: 91.245

Review 4.  Electrolytes and Cardiovascular Disease Risk.

Authors:  Jonathan Bennett; Alysha L Deslippe; Christine Crosby; Sally Belles; Jinan Banna
Journal:  Am J Lifestyle Med       Date:  2020-05-08

5.  Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map.

Authors:  Safi U Khan; Muhammad U Khan; Haris Riaz; Shahul Valavoor; Di Zhao; Lauren Vaughan; Victor Okunrintemi; Irbaz Bin Riaz; Muhammad Shahzeb Khan; Edo Kaluski; M Hassan Murad; Michael J Blaha; Eliseo Guallar; Erin D Michos
Journal:  Ann Intern Med       Date:  2019-07-09       Impact factor: 25.391

6.  Effectiveness of Changes in Diet Composition on Reducing the Incidence of Cardiovascular Disease.

Authors:  Ilaria Calabrese; Gabriele Riccardi
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

Review 7.  Salt Restriction in Diabetes.

Authors:  Peter M Clifton; Jennifer B Keogh
Journal:  Curr Diab Rep       Date:  2015-09       Impact factor: 4.810

Review 8.  Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride.

Authors:  Niels Albert Graudal; Thorbjorn Hubeck-Graudal; Gesche Jurgens
Journal:  Cochrane Database Syst Rev       Date:  2017-04-09

Review 9.  Salt Sensitivity: Challenging and Controversial Phenotype of Primary Hypertension.

Authors:  Rossella Iatrino; Paolo Manunta; Laura Zagato
Journal:  Curr Hypertens Rep       Date:  2016-09       Impact factor: 5.369

10.  Understanding the science that supports population-wide salt reduction programs.

Authors:  Jacqui Webster; Temo Waqanivalu; JoAnne Arcand; Kathy Trieu; Francesco P Cappuccio; Lawrence J Appel; Mark Woodward; Norm R C Campbell; Rachael McLean
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.